论文部分内容阅读
目的探讨新型抗血管内皮生长因子(VEGF)康柏西普注射液对视网膜Müller细胞生长和水通道蛋白4(AQP4)表达的影响。方法将培养的人视网膜Müller细胞分为5组:正常对照组、高糖组(25 mmol/L葡萄糖)和药物组(给予低剂量0.25μg/mL、中剂量2.5μg/mL、高剂量25μg/mL的康柏西普)。采用酶联免疫吸附试验(ELISA)检测细胞上清液中VEGF的分泌情况,采用CCK8法和流式细胞术检测细胞生长情况,采用半定量反转录聚合酶链反应(RT-PCR)和Western印迹法检测AQP4的表达情况。结果康柏西普显著抑制了高糖状态下Müller细胞VEGF的分泌,但对高糖处理引起的Müller细胞活力下降并无明显改善;康柏西普明显抑制了高糖诱导的Müller细胞AQP4表达增加,并呈剂量依赖性。结论康柏西普是一种高效的VEGF拮抗剂,可以通过降低Müller细胞AQP4的表达缓解视网膜水肿,但对Müller细胞本身的生长并无影响。
Objective To investigate the effect of a new anti-vascular endothelial growth factor (CONC) injection on the growth of retinal Müller cells and the expression of aquaporin-4 (AQP4). Methods The cultured human retinal Müller cells were divided into 5 groups: normal control group, high glucose group (25 mmol / L glucose) and drug group (low dose 0.25μg / mL, medium dose 2.5μg / mL, high dose 25μg / mL of Compstax). The secretion of VEGF in the cell supernatant was detected by enzyme linked immunosorbent assay (ELISA). The cell growth was detected by CCK8 and flow cytometry. Semi-quantitative RT-PCR and Western blot Western blotting was used to detect the expression of AQP4. Results Compstax inhibited the secretion of VEGF in Müller cells under high glucose condition, but did not decrease the vitality of Müller cells induced by high glucose. Concomitantly inhibited the increase of AQP4 expression in Müller cells induced by high glucose , And in a dose-dependent manner. Conclusions Compaqepip is a potent VEGF antagonist that can alleviate retinal edema by decreasing the expression of AQP4 in Müller cells, but has no effect on the growth of Müller cells.